

## DIRECTORS, OFFICERS, FOUNDERS AND ADVISORS

### Board of Directors:

<b>Kapil Dhingra, M.D.</b> .....	Drug development expert, former head of Roche Oncology Leadership Team; led growth of oncology franchise from \$800m to >\$10 Billion per annum.
<b>Michael Gargano</b> .....	Managing Director of Argent Ventures, real estate developer and investor in major US cities, primarily New York, LA and Miami.
<b>Colin Goddard, Ph.D.</b> .....	CEO of OSI Pharmaceuticals from 1998 until its \$4B acquisition by Astellas Pharmaceuticals in June 2010; joined OSI as a scientist in 1989; presided over transition from \$64M market cap to fully integrated biopharmaceutical company with \$500M in revenue in 2010. Currently a director of Human Genome Sciences, Zelos and PanOptica.
<b>Alan Lewis, Ph.D.</b> .....	Chairman and CEO of Ambit Biosciences; previously President of Research at Celgene, CEO of Novocell, CEO of Signal Therapeutics, and VP of Research at Wyeth.
<b>Viren Mehta</b> .....	25+ year career advising biopharmaceutical industry worldwide: Founding Partner of Mehta Partners and earlier of Mehta & Islay; Management at Merck & Co.; Recently BOD at OSI Pharmaceuticals.
<b>Mark Simon</b> .....	Former head of healthcare investment banking CitiGroup, renown biotech financier, has raised more than \$30 Billion in public and private financings and many global strategic partnerships, current industry advisor.

### Management:

<b>Colin Goddard, Ph.D.</b> .....	CEO of OSI Pharmaceuticals from 1998 until its \$4B acquisition by Astellas Pharmaceuticals in June 2010; joined OSI as a scientist in 1989; presided over transition from \$64M market cap to fully integrated biopharmaceutical company with \$500M in revenue in 2010. Currently a director of Human Genome Sciences, Zelos and PanOptica.
Executive Chairman	

<b>Derek A. Small</b> ..... Interim/ founding CEO, Director	President of Luson Bioventures: focuses on starting new biotech ventures, drug developer of multiple molecules to human studies, raised >\$50m in start up financing; part of early or founding management at Semafore Pharmaceuticals, Simdesk, Kinagen, Endgenitor, Naurex, and other start ups
<b>Lee Arnold, Ph.D.</b> ..... Chief Scientific Officer	22+ years in pharma discovery; former VP of US Research for OSI, inventor of Tarceva®, leading cancer drug >\$1 Billion sales in 08, and 6 other molecules into clinical development; previously at Abbott, Pfizer.
<b>Jim Schulz</b> ..... Head of Finance	Partner in Upward Focus, LLC; over 20 years of experience in public accounting, Fortune 500 and start-up companies; focus expertise in outsourced financial support for small biotech companies including SonarMed Inc., Tigas Pharmaceuticals, and Naurex Inc.

#### **Founding Scientists:**

<b>Francis Barany, Ph.D.</b> ..... Founder, Chief Scientist	Professor at Weill Medical College of Cornell University; Inventor on 34 issued patents including ligase chain reaction (LCR) and others generating >\$1.3B sales; >110 publications; numerous awards including Scientific American Top 50 Scientists in 2004; Ph.D. from Rockefeller 1981
<b>Donald Bergstrom, Ph.D.</b> ..... Founder, Chief Chemist	Walther Professor of Medicinal Chemistry at Purdue University; 13 patents and >120 publications; numerous awards and advisor to several start-up biotech; Chemistry Ph.D. from Berkley in 1970.
<b>Maneesh Pingle, Ph.D.</b> ..... Founder, Sr. Science Advisor	Instructor at Weill Medical College of Cornell University in the department of Microbiology; Ph.D. from Purdue University in Medicinal Chemistry and Molecular Pharmacology.

**Scientific Advisors:**

<b>Paul Anderson, Ph.D.</b> .....	Leading drug discovery expert, chemist, former head of discovery at, BMS and Merck/Dupont; awarded the ACS Priestley Medal, has discovered or developed several approved new drugs such as TRUSOPT, ZOCOR, CRIXIVAN and SUSTIVA that have achieved over \$5 billion in aggregate annual sales.
<b>Homer L. Pearce, Ph.D.</b> .....	Leading drug discovery expert, chemist, former head of oncology discovery & dev, Eli Lilly; awarded ACS Hero of Chemistry Award, has discovered or developed >25 clinical candidates and 3 FDA approved drugs with aggregate annual sales over \$3 billion such as Gemzar, Alimta, and Oncotak.
<b>Charles Fisher, M.D.</b> .....	35+ year career in clinical investigation and drug development: previously DVP, Global Pharmaceutical Development, Abbott Laboratories; Executive Director, Clinical Research Fellow, Eli Lilly (Xigris®); Professor and Head, Critical Care Medicine at the Cleveland Clinic Foundation
<b>Kapil Dhingra, M.D.</b> .....	Drug development expert, former head of Roche Oncology Leadership Team; led growth of oncology franchise from \$800m to >\$10 Billion per annum.